FDA Prioritizes Amivantamab Review in Head-and-Neck Cancer

Company Johnson & Johnson Event Type Regulatory Designation (Priority Review, Supplemental Application) Modality EGFR x MET bispecific antibody, subcutaneous formulation Asset RYBREVANT FASPRO (amivantamab plus hyaluronidase) Target EGFR and MET Disease Area Recurrent or metastatic head-and-neck squamous cell carcinoma after platinum chemotherapy and PD-1/PD-L1 therapy…